Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
CN Stock MarketDetailed Quotes
Shanghai Shyndec Pharmaceutical (600420)
- 9.59
- -0.01-0.10%
Market Closed Apr 30 15:00 CST
12.86BMarket Cap17.89P/E (TTM)
9.60High9.45Low88.11KlotVolume9.59Open9.60Prev Close84.10MTurnover0.66%Turnover Ratio13.66P/E (Static)1.34BShares11.7052wk High0.92P/B12.86BFloat Cap9.4552wk Low10.56Limit Up1.34BShs Float29.02Historical High8.64Limit Down1.56%Range %-0.23Historical Low0.30Dividend TTM9.54Avg Price44.35KlotAsk3.13%Div Yield TTM100Lot Size42.98KlotBid
Shanghai Shyndec Pharmaceutical (600420) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -20.81%2.06B | -14.39%9.36B | -19.47%6.92B | -18.16%4.88B | -16.54%2.61B | -9.38%10.94B | -6.21%8.59B | -7.52%5.96B | -8.60%3.12B | -6.86%12.07B |
| Operating revenue | -20.81%2.06B | -14.39%9.36B | -19.47%6.92B | -18.16%4.88B | -16.54%2.61B | -9.38%10.94B | -6.21%8.59B | -7.52%5.96B | -8.60%3.12B | -6.86%12.07B |
| Other operating revenue | ---- | -13.56%145.01M | ---- | -21.53%68.73M | ---- | -40.71%167.77M | ---- | -49.79%87.58M | ---- | 88.93%282.98M |
| Total operating cost | -13.17%1.83B | -11.63%8.14B | -18.04%5.86B | -19.51%3.98B | -19.70%2.11B | -16.28%9.21B | -13.29%7.15B | -14.87%4.94B | -14.65%2.63B | -8.67%11B |
| Operating cost | -12.13%1.44B | -4.79%6.33B | -10.93%4.62B | -13.28%3.12B | -11.36%1.64B | -10.73%6.65B | -7.45%5.18B | -8.22%3.6B | -9.00%1.85B | -7.23%7.44B |
| Operating tax surcharges | -0.36%25.34M | -12.90%114.58M | -23.44%70.32M | -24.78%50.81M | -33.77%25.43M | -4.76%131.55M | -3.97%91.85M | 3.48%67.55M | 32.16%38.4M | 20.82%138.12M |
| Operating expense | -33.95%120.81M | -53.95%530.43M | -63.39%354.82M | -62.69%267.35M | -59.67%182.92M | -46.51%1.15B | -42.03%969.12M | -42.79%716.48M | -36.65%453.6M | -21.59%2.15B |
| Administration expense | -7.42%157.66M | -3.72%763.78M | -5.52%526.07M | -8.67%341.35M | -7.52%170.3M | 3.01%793.27M | 0.71%556.79M | 3.83%373.76M | 7.40%184.15M | 12.59%770.07M |
| Financial expense | 138.43%7.74M | 55.82%-39.18M | 41.75%-39.14M | 45.46%-33.57M | 4.49%-20.13M | -17.47%-88.68M | -29.92%-67.19M | -54.55%-61.56M | -222.74%-21.07M | -63.65%-75.49M |
| -Interest expense (Financial expense) | -61.72%538.23K | -88.11%4.39M | -85.05%4.16M | -84.79%2.84M | -85.16%1.41M | -36.27%36.89M | -42.08%27.84M | -50.47%18.7M | -46.32%9.47M | -46.06%57.88M |
| -Interest Income (Financial expense) | 63.79%-5.17M | 49.88%-43.59M | 50.59%-36.65M | 51.35%-26.45M | 37.47%-14.28M | 20.23%-86.97M | -0.78%-74.17M | -10.83%-54.38M | -37.78%-22.84M | -83.71%-109.02M |
| Research and development | -28.82%78.82M | -23.29%441.79M | -20.32%331.63M | -6.17%229.5M | -8.94%110.73M | 1.14%575.93M | 10.43%416.21M | 0.42%244.6M | 9.92%121.61M | 9.31%569.43M |
| Credit Impairment Loss | 23.33%-8.81M | -764.93%-15.67M | -323.56%-16.98M | -478.55%-20.81M | -317.25%-11.5M | -86.95%2.36M | -11.58%-4.01M | 78.28%-3.6M | 78.39%-2.76M | 2.64%18.05M |
| Asset Impairment Loss | 43.47%-10.86M | 26.36%-124.09M | 37.30%-58.84M | -242.01%-38.68M | -490.96%-19.21M | -113.01%-168.5M | -83.11%-93.83M | 60.03%-11.31M | 76.34%-3.25M | -69.38%-79.11M |
| Other net revenue | 132.59%26.33M | 276.10%88.92M | 76.38%43.39M | -76.19%17.97M | -59.21%11.32M | 107.91%23.64M | 792.80%24.6M | 298.15%75.47M | 257.16%27.75M | -77.62%11.37M |
| Invest income | 41.89%29.35M | 108.87%133.9M | 87.11%68.29M | 143.67%41.03M | 734.17%20.68M | 133.51%64.11M | 170.87%36.5M | 310.22%16.84M | 269.21%2.48M | 1,071.97%27.45M |
| -Including: Investment income associates | 18.19%10.52M | 77.45%24.4M | 269.44%22.09M | 185.67%15.03M | 880.00%8.9M | 145.38%13.75M | 197.21%5.98M | 199.66%5.26M | 3.98%-1.14M | 13.24%5.6M |
| Asset deal income | 84.23%-71.25K | 91.53%-2.65M | 86.50%-741.78K | 96.81%-65.42K | 79.44%-451.81K | 1.68%-31.31M | -356.62%-5.49M | -104.08%-2.05M | -2,260.59%-2.2M | -2,785.98%-31.85M |
| Other revenue | -23.27%16.73M | -37.94%97.42M | -43.50%51.66M | -51.72%36.49M | -34.88%21.8M | 104.38%156.99M | 134.36%91.44M | 284.81%75.59M | 221.94%33.47M | -2.37%76.81M |
| Operating profit | -49.05%259.35M | -25.02%1.31B | -24.83%1.1B | -16.10%920.16M | -2.96%509.06M | 61.97%1.75B | 60.80%1.47B | 81.30%1.1B | 62.77%524.6M | 11.95%1.08B |
| Add:Non operating Income | -82.61%1.09M | 135.71%35.97M | 198.24%29.95M | 59.45%12.36M | 679.53%6.26M | -40.14%15.26M | -54.45%10.04M | -57.34%7.75M | -72.33%802.85K | -41.53%25.49M |
| Less:Non operating expense | 184.04%12.12M | -76.74%21.9M | -16.38%18.17M | -57.94%7.59M | -75.47%4.27M | 791.53%94.13M | 126.68%21.72M | 226.24%18.05M | 2,501.30%17.4M | -58.77%10.56M |
| Total profit | -51.41%248.32M | -20.65%1.33B | -23.42%1.12B | -14.86%924.93M | 0.60%511.05M | 52.57%1.67B | 57.38%1.46B | 75.92%1.09B | 56.54%508M | 11.43%1.1B |
| Less:Income tax cost | -35.80%56.18M | -45.62%185.42M | -29.15%182.26M | -22.44%154.75M | 6.53%87.51M | 158.41%340.97M | 100.80%257.24M | 93.63%199.51M | 63.42%82.15M | 13.13%131.95M |
| Net profit | -54.63%192.14M | -14.26%1.14B | -22.20%933.23M | -13.16%770.18M | -0.54%423.54M | 38.10%1.33B | 50.40%1.2B | 72.37%886.89M | 55.27%425.86M | 11.20%964.61M |
| Net profit from continuing operation | -54.63%192.14M | -14.26%1.14B | -22.20%933.23M | -13.16%770.18M | -0.54%423.54M | 38.10%1.33B | 50.40%1.2B | 72.37%886.89M | 55.27%425.86M | 11.20%964.61M |
| Less:Minority Profit | -13.50%53.74M | -19.28%200.56M | -46.08%132.06M | -41.74%98.11M | -34.33%62.13M | -8.90%248.46M | 4.85%244.92M | -0.69%168.41M | -0.46%94.6M | 13.78%272.73M |
| Net profit of parent company owners | -61.71%138.4M | -13.11%941.6M | -16.07%801.17M | -6.46%672.07M | 9.10%361.41M | 56.62%1.08B | 69.27%954.53M | 108.29%718.48M | 84.83%331.26M | 10.21%691.88M |
| Earning per share | ||||||||||
| Basic earning per share | -61.71%0.1032 | -13.11%0.7021 | -16.06%0.5974 | -6.46%0.5011 | 9.11%0.2695 | 48.72%0.808 | 57.87%0.7117 | 87.31%0.5357 | 61.54%0.247 | -11.12%0.5433 |
| Diluted earning per share | -61.71%0.1032 | -13.11%0.7021 | -16.06%0.5974 | -6.46%0.5011 | 9.11%0.2695 | 48.72%0.808 | 57.87%0.7117 | 87.31%0.5357 | 79.51%0.247 | 0.07%0.5433 |
| Other composite income | -212.70%-197.05K | -160.55%-290.96K | -160.55%-290.96K | 92.56%174.84K | -50.74%-111.67K | -51.39%-111.67K | -81.75%90.8K | |||
| Other composite income of parent company owners | ---- | -212.70%-197.05K | -160.55%-290.96K | -160.55%-290.96K | ---- | 92.56%174.84K | -50.74%-111.67K | -51.39%-111.67K | ---- | -81.75%90.8K |
| Total composite income | -54.63%192.14M | -14.28%1.14B | -22.21%932.94M | -13.18%769.89M | -0.54%423.54M | 38.10%1.33B | 50.40%1.2B | 72.37%886.78M | 55.29%425.86M | 11.14%964.7M |
| Total composite income of parent company owners | -61.71%138.4M | -13.14%941.4M | -16.09%800.88M | -6.49%671.78M | 9.10%361.41M | 56.62%1.08B | 69.27%954.41M | 108.30%718.37M | 84.86%331.26M | 10.14%691.97M |
| Total composite income of minority owners | -13.50%53.74M | -19.28%200.56M | -46.08%132.06M | -41.74%98.11M | -34.33%62.13M | -8.90%248.46M | 4.85%244.92M | -0.69%168.41M | -0.46%94.6M | 13.78%272.73M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm